Checked
Federal dataHealth
Capmatinib
Published by U.S. Food and Drug Administration · Updated 03/17/2025 · Yearly
- Last updated
- 03/17/2025
- First published 09/16/2016
- Update frequency
- Yearly
- Formats
- Web only
- Coverage
- Nationwide
- Federal data
About this dataset
TABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coated tablets in 150 mg and 200 mg strengths and works by inhibiting certain proteins involved in cancer cell growth. This information was generated using AI and is provided for informational and research purposes only.
Files and access
Links open the official government source
- Capmatinibaccessdata.fda.govWeb page
Links open outside websites we do not control.
Frequently asked questions
- Who publishes Capmatinib?
- U.S. Food and Drug Administration, part of U.S. Department of Health & Human Services, publishes this dataset on Data.gov.
- How often is it updated?
- The publisher lists the update frequency as yearly. The last update was on 03/17/2025.
- How do I download it?
- Use the official source link above to view or request the data.
Similar data from other publishers
- CapmatinibState of VirginiaTABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coatedUpdated 09/29/2026
- CapmatinibState of VirginiaTABRECTA (capmatinib) is an oral prescription medication from Novartis Pharmaceuticals Corporation, approved to treat adults with metastatic non-small cell lung cancer (NSCLC) that has a specific genetic mutation (MET exon 14 skipping). It comes as film-coatedUpdated 05/26/2026
- CabozantinibState of VirginiaCABOMETYX is a prescription medication containing cabozantinib, a kinase inhibitor that helps treat certain advanced cancers. It comes as oral tablets in strengths of 20 mg, 40 mg, and 60 mg, manufactured by Exelixis, Inc. This information was generated using Updated 03/23/2026
- FostamatinibState of VirginiaTavalisse (fostamatinib) is an oral prescription drug manufactured by Rigel Pharmaceuticals, Inc., available as 100mg and 150mg tablets. It is used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to Updated 05/26/2026
- FostamatinibState of VirginiaTavalisse (fostamatinib) is an oral prescription drug manufactured by Rigel Pharmaceuticals, Inc., available as 100mg and 150mg tablets. It is used to treat low platelet counts in adults with chronic immune thrombocytopenia (ITP) who haven't responded well to Updated 09/29/2026
Where this catalog comes from
- Data.gov CatalogU.S. General Services Administration
- State and local open data portalsSocrata Discovery API
- State and city CKAN portalsCalifornia, Virginia, Boston, Houston and more
- Government ArcGIS Hub sitesCity and county GIS data
Catalog checked 10/24/2026
We list dataset descriptions only. Downloads and APIs link straight to the official government source, which holds the current version and its terms of use.
Source: Data.gov · Last updated 10/24/2026 · Listing only; the data stays with the publisher
Share: